FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004481399> ?p ?o ?g. }

• W3004481399 endingPage "333" @default.
• W3004481399 startingPage "324" @default.
• W3004481399 abstract "Objective In the context of systemic autoimmunity, that is systemic lupus erythematosus (SLE) or adult-onset Still’s disease (AOSD), secondary haemophagocytic lymphohistiocytosis (HLH; also referred to as macrophage activation syndrome (MAS) or more recently MAS-HLH) is a rare and potentially life-threatening complication. Pathophysiological hallmarks are aberrant macrophage and T cell hyperactivation and a systemic cytokine flare, which generate a sepsis-like, tissue-damaging, cytopenic phenotype. Unfortunately, for adult MAS-HLH we lack standardized treatment protocols that go beyond high-dose corticosteroids. Consequently, outcome data are scarce on steroid refractory cases. Aside from protocols based on treatment with calcineurin inhibitors, etoposide, cyclophosphamide and anti-IL-1, favourable outcomes have been reported with the use of intravenous immunoglobulin (IvIG) and plasma exchange (PE). Methods Here we report a retrospective series of steroid refractory MAS-HLH, the associated therapeutic regimes and outcomes. Results In this single-centre experience, 6/8 steroid refractory patients survived (median follow-up: 54.4 (interquartile range: 23.3–113.3) weeks). All were initially treated with PE, which induced partial response in 5/8 patients. Yet, all patients required escalation of immunosuppressive therapies. One case of MAS-HLH in new-onset AOSD had to be escalated to etoposide, whereas most SLE-associated MAS-HLH patients responded well to cyclophosphamide. Relapses occurred in 2/8 cases. Conclusion Together, early use of PE is at most a supportive measure, not a promising monotherapy of adult MAS-HLH. In refractory cases, conventional cytoreductive therapies (i.e. cyclophosphamide and etoposide) constitute potent and reliable rescue approaches, whereas IvIG, anti-thymoglobulin, and biologic agents appear to be less effective." @default.
• W3004481399 created "2020-02-14" @default.
• W3004481399 creator A5000033355 @default.
• W3004481399 creator A5001250695 @default.
• W3004481399 creator A5008927439 @default.
• W3004481399 creator A5028813168 @default.
• W3004481399 creator A5039653665 @default.
• W3004481399 creator A5041212406 @default.
• W3004481399 creator A5058656687 @default.
• W3004481399 creator A5071466038 @default.
• W3004481399 creator A5076736029 @default.
• W3004481399 creator A5086900919 @default.
• W3004481399 creator A5089262106 @default.
• W3004481399 date "2020-02-03" @default.
• W3004481399 modified "2023-09-28" @default.
• W3004481399 title "Adult macrophage activation syndrome–haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ – a single centre reflection" @default.
• W3004481399 cites W1585868534 @default.
• W3004481399 cites W1925777576 @default.
• W3004481399 cites W1998454545 @default.
• W3004481399 cites W2014275955 @default.
• W3004481399 cites W2055476027 @default.
• W3004481399 cites W2065665498 @default.
• W3004481399 cites W2068658592 @default.
• W3004481399 cites W2104164819 @default.
• W3004481399 cites W2163067702 @default.
• W3004481399 cites W2165127856 @default.
• W3004481399 cites W2304277276 @default.
• W3004481399 cites W2418230151 @default.
• W3004481399 cites W2463446906 @default.
• W3004481399 cites W2611521090 @default.
• W3004481399 cites W2736468800 @default.
• W3004481399 cites W2772443115 @default.
• W3004481399 cites W2790123356 @default.
• W3004481399 cites W2794668346 @default.
• W3004481399 cites W2802314465 @default.
• W3004481399 cites W2807441801 @default.
• W3004481399 cites W2823118617 @default.
• W3004481399 cites W2895463588 @default.
• W3004481399 cites W2910660965 @default.
• W3004481399 cites W2936019126 @default.
• W3004481399 cites W2936410494 @default.
• W3004481399 cites W4251454972 @default.
• W3004481399 doi "https://doi.org/10.1177/0961203320901594" @default.
• W3004481399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32013725" @default.
• W3004481399 hasPublicationYear "2020" @default.
• W3004481399 type Work @default.
• W3004481399 sameAs 3004481399 @default.
• W3004481399 citedByCount "14" @default.
• W3004481399 countsByYear W30044813992020 @default.
• W3004481399 countsByYear W30044813992021 @default.
• W3004481399 countsByYear W30044813992022 @default.
• W3004481399 countsByYear W30044813992023 @default.
• W3004481399 crossrefType "journal-article" @default.
• W3004481399 hasAuthorship W3004481399A5000033355 @default.
• W3004481399 hasAuthorship W3004481399A5001250695 @default.
• W3004481399 hasAuthorship W3004481399A5008927439 @default.
• W3004481399 hasAuthorship W3004481399A5028813168 @default.
• W3004481399 hasAuthorship W3004481399A5039653665 @default.
• W3004481399 hasAuthorship W3004481399A5041212406 @default.
• W3004481399 hasAuthorship W3004481399A5058656687 @default.
• W3004481399 hasAuthorship W3004481399A5071466038 @default.
• W3004481399 hasAuthorship W3004481399A5076736029 @default.
• W3004481399 hasAuthorship W3004481399A5086900919 @default.
• W3004481399 hasAuthorship W3004481399A5089262106 @default.
• W3004481399 hasConcept C121332964 @default.
• W3004481399 hasConcept C126322002 @default.
• W3004481399 hasConcept C142424586 @default.
• W3004481399 hasConcept C203014093 @default.
• W3004481399 hasConcept C2776694085 @default.
• W3004481399 hasConcept C2776755627 @default.
• W3004481399 hasConcept C2777178219 @default.
• W3004481399 hasConcept C2778119113 @default.
• W3004481399 hasConcept C2779079688 @default.
• W3004481399 hasConcept C2779134260 @default.
• W3004481399 hasConcept C2779613421 @default.
• W3004481399 hasConcept C71924100 @default.
• W3004481399 hasConcept C87355193 @default.
• W3004481399 hasConceptScore W3004481399C121332964 @default.
• W3004481399 hasConceptScore W3004481399C126322002 @default.
• W3004481399 hasConceptScore W3004481399C142424586 @default.
• W3004481399 hasConceptScore W3004481399C203014093 @default.
• W3004481399 hasConceptScore W3004481399C2776694085 @default.
• W3004481399 hasConceptScore W3004481399C2776755627 @default.
• W3004481399 hasConceptScore W3004481399C2777178219 @default.
• W3004481399 hasConceptScore W3004481399C2778119113 @default.
• W3004481399 hasConceptScore W3004481399C2779079688 @default.
• W3004481399 hasConceptScore W3004481399C2779134260 @default.
• W3004481399 hasConceptScore W3004481399C2779613421 @default.
• W3004481399 hasConceptScore W3004481399C71924100 @default.
• W3004481399 hasConceptScore W3004481399C87355193 @default.
• W3004481399 hasIssue "3" @default.
• W3004481399 hasLocation W30044813991 @default.
• W3004481399 hasLocation W30044813992 @default.
• W3004481399 hasOpenAccess W3004481399 @default.
• W3004481399 hasPrimaryLocation W30044813991 @default.
• W3004481399 hasRelatedWork W2005607780 @default.
• W3004481399 hasRelatedWork W2316604092 @default.
• W3004481399 hasRelatedWork W2413530138 @default.

• next